Clinical Trial

VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this phase 1/2 trial is to test the safety and efficacy of Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT in treating patients with higher-risk MDS.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-18; most recent amendment 2024-09-28.
Status change: Not Yet Recruiting → Recruiting 2024-09-28
Trial Details
NCT Number NCT06471946
Lead Sponsor Navy General Hospital, Beijing
Conditions Higher-risk Myelodysplastic Syndromes
Enrollment 54 participants
Start Date 2024-10-01
Primary Completion 2029-09-01 (estimated)
Study Completion 2030-09-01 (estimated)
Updated on ClinicalTrials.gov 2024-10-01